Ms. Gregory was appointed interim Chief Executive Officer November 2013. She had been our Executive Vice President and Chief Financial Officer, since July, 2012. Prior to ContraFect, Ms. Gregory was President and CEO of Five Prime Therapeutics, Inc., a clinical-stage, privately held biotechnology company discovering and developing innovative protein and antibody therapeutics in the fields of oncology and immunology. Prior to Five Prime, Ms. Gregory was Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Ms. Gregory has been actively involved in a variety of public and private financings, including a private equity agreement designed to provide financing of up to $550 million for Lexicon and Lexicon's $220 million initial public offering. While at FivePrime and Lexicon, she led transactions for several strategic partnerships including those with GlaxoSmithKline, Human Genome Sciences, Genentech, Inc., Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. In addition, she led the negotiations for Lexicon's acquisition of the chemistry company that provided the foundation for Lexicon's novel drug programs. Prior to joining Lexicon, Ms. Gregory was an investment banker where she served as the head of investment banking for Punk, Ziegel & Company, a specialty technology and healthcare investment banking firm and was an investment banker with Dillon, Read & Co., Inc. She currently serves as a Director on the board of Clinipace on behalf of and as Special Advisor to Morgan Stanley Expansion Capital and on the board of The Global TB Alliance for Drug Development, primarily funded by the Gates Foundation.
Ms. Gregory received her B.A. from George Washington University's Elliott School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from the Wharton School of the University of Pennsylvania.
Dr. Huang has more than 10 years of clinical research and industry experience. Prior to joining ContraFect, Dr. Huang served as the Global Medical Director of Medical Affairs for Pfizer Inc, where he played a key role in the development efforts of Zyvox for MRSA-associated infections. Previously, he was the Associate Director of Clinical Development for Boehringer Ingelheim, where he played a key role in the development of Aptivus and Viramune for HIV infections. Dr. Huang previously served as an Assistant Professor at Baylor College of Medicine, and currently serves as an Adjunct Clinical Professor at the University of New Jersey Medicine and Dentistry, and is an attending physician at the Veterans Affairs Medical Center at Manhattan.
Dr. Huang received his M.D. and Ph.D. from the University of Texas at Houston Medical School. He is board certified in internal medicine and infectious diseases. He completed his internal medicine residency at the University of Texas at Southwestern and his infectious diseases fellowship at Baylor College of Medicine. He is a fellow of the American College of Physicians and a fellow of the Infectious Diseases Society of America. Dr. Huang's research interest has focused on the epidemiology, pathogenesis and treatment of viruses and bacteria, including multi-drug resistant pathogens, and has resulted in over 100 peer-reviewed publications.
Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp prior to her role as Vice President of Finance and Administration at DCM, a tele-services firm supporting the performing arts. Ms. Dong also held the positions of COO/CFO at Semaphore, a project management software development firm.
Ms. Dong received her B.A. degree from Yale University and a MPPM degree from The Wharton School at the University of Pennsylvania. She started her career as a management consultant at Ernst & Young.
Dr. Wittekind has more than 20 years of industry experience in biotechnology research and management. Prior to joining ContraFect, Dr. Wittekind served as the Executive Director of Research for Amgen Inc, where he directed the Protein Science Department at the Amgen-Seattle site. While at Amgen, he was involved in the discovery efforts for multiple protein therapeutics currently undergoing clinical trials, including antibodies, antibody-drug conjugates, and protein fusions. Previously, Dr. Wittekind was the Director of Process Development for Phylos Inc, where he played a key role in the development of alternate scaffold therapeutic discovery, design, and production. Dr. Wittekind has also served as the Associate Director of the Gene Expression & Protein Biochemistry Department of the Bristol-Myers Squibb Pharmaceutical Research Institute, directing groups in both the Lawrenceville and Hopewell NJ sites leading structural biology research as well as protein and small molecule therapeutic efforts.
Dr. Wittekind received his Ph.D. from the University of Wisconsin-Madison in Biochemistry and followed with postdoctoral studies at the University of Washington. Dr. Wittekindís research interests have encompassed genetics, molecular biology, structural biology, and engineering of novel antibodies and proteins, resulting in over 40 publications and patents.
Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmaceuticals, Inc. In this capacity, he was responsible for the financial management of Lexiconís partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexiconís development programs.
Mr. Messinger received his B.B.A degree in accounting from the University of Michigan. He started his career as an auditor at Ernst & Young, LLP.
Dr. Kappel joined ContraFect in 2009 as the company's second employee and the Head of Business Development. Since the beginning, Dr. Kappel has been involved in all aspects of the company, including licensing of the company's key technologies, participation in the financings of the company, and establishing scientific collaborations with academic and corporate partners.
Dr. Kappel previously was a Senior Consultant at Easton Associates, LLC, a life science consulting firm. In this capacity, he performed a wide range of activities, including the assessment of preclinical and clinical compounds for Pharmaceutical and Biotechnology companies.
Dr. Kappel received his B.A. in chemistry from Emory University. He subsequently obtained his Ph.D. in immunology and pharmacology from the Weill Graduate School of Medical Sciences and the Memorial Sloan-Kettering Cancer Center. Dr. Kappel holds an MBA from the S.C. Johnson Graduate School of Management at Cornell University.
Mr. Couto has more than 20 years of experience in operations management. Prior to joining ContraFect, he served as a Vice President of Commercial Manufacturing Operations for Merck Sharp & Dohme Biologics UK Ltd. Previously, he was Director of Manufacturing for Nuvelo Inc., where he was responsible for 7 World Wide Contract Manufacturing sites. Mr. Couto also served in Director positions at Genzyme Transgenics Corp., Advanced Biosystems Corp., ImmuCell Corp., and Sepracor Corp. Mr. Couto holds patents for several novel separation technologies such as Bulk Protein Crystallization, HPTFF, and SMB.
Mr. Couto received his B.S. degree in chemical engineering from Rensselaer Polytechnic Institute.